AstraZeneca PLC (AZN)vsTivic Health Systems Inc (TIVC)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
TIVC
Tivic Health Systems Inc
$0.96
-4.95%
HEALTHCARE · Cap: $3.83M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 12186414% more annual revenue ($58.74B vs $482,000). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TIVC
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
-14.2%
Fair Value
$0.76
Current Price
$0.96
$0.20 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
15.9% revenue growth
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TIVC
The strongest argument for TIVC centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : TIVC
The primary concerns for TIVC are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while TIVC is a growth play — different risk/reward profiles.
TIVC carries more volatility with a beta of 1.84 — expect wider price swings.
TIVC is growing revenue faster at 15.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 37/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Tivic Health Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Tivic Health Systems Inc (TIVC) is a pioneering medical technology firm focused on developing non-invasive bioelectronic therapies aimed at addressing chronic conditions, particularly allergic rhinitis. Leveraging its proprietary platform and extensive clinical expertise, Tivic Health is committed to delivering innovative solutions that not only meet critical patient needs but also optimize healthcare delivery. Positioned at the vanguard of the burgeoning bioelectronic medicine landscape, the company is set to seize emerging market opportunities, significantly improving patient outcomes and establishing new benchmarks in chronic condition management.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?